Ritedose Announces Manufacturing for Tenpoint Therapeutics’ Presbyopia Eye Drop

April 8, 2026

Ritedose presbyopia eye drop manufacturing

Partnership Signals Commercial Readiness and Manufacturing Strength for Groundbreaking Ophthalmic Treatment.

COLUMBIA, SC – APRIL 8, 2026 — The Ritedose Corporation , Inc. (Ritedose), the largest contract development manufacturing organization (CDMO) in the United States specializing in sterile Blow-Fill-Seal (BFS) production of unit dose solutions for the ophthalmic and respiratory markets, is partnering with Tenpoint Therapeutics, Ltd. to manufacture YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, the first and only dual-agent eye drop FDA-approved for the treatment of presbyopia.

The selection of Ritedose as a CDMO reflects a deliberate commitment to commercial readiness and supply security. In the ophthalmic space, where validated sterile manufacturing and rigorous quality oversight are critical to earning the confidence of investors, physicians, and the broader market, partnering with a proven manufacturer is a strategic imperative. By aligning with Ritedose and its more than 25 years of experience in sterile ophthalmic and respiratory manufacturing, Tenpoint has meaningfully de-risked its production pathway and demonstrated the discipline to choose best-in-class partners in bringing YUVEZZI to patients at scale.

“Our leading aseptic manufacturing capabilities make Ritedose the ideal partner to deliver safe and effective doses of YUVEZZI to patients,” said Jody Chastain, president and CEO of Ritedose. “We have been serving the ophthalmic and the respiratory markets for over 25 years, and this partnership reflects what that track record means in practice. Tenpoint Therapeutics chose us—a CDMO with proven execution, supply chain security and an uncompromised standard of quality. We are proud to help Tenpoint Therapeutics bring this treatment to the patients who need it.”

“Ritedose is proud to work alongside Tenpoint Therapeutics on the manufacturing of national launch quantities of YUVEZZI so this treatment can be available to all presbyopia patients who need it,” continued Chastain.

About The Ritedose Corporation

Ritedose is the largest sterile contract development manufacturing organization (CDMO) in the US specializing in sterile Blow Fill Seal (BFS) technology that ensures sterile, consistent, and safe unit dose delivery. The company’s process guides the development of molecules from clinical trials to commercialization of branded and generic inhalation and ophthalmic medications. With a focus on quality, innovation, and customer satisfaction, Ritedose partners with leading pharmaceutical companies to deliver safe, effective, and reliable medications that improve patient outcomes. For more information about Ritedose and its services: visit Ritedose.com

About Tenpoint Therapeutics

Tenpoint Therapeutics Ltd. is a commercial-stage ophthalmic pharmaceuticals company focused on the commercialization of YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution ) 2.75%/0.1%, the first and only dual-agent eye drop for the treatment of presbyopia, a condition that affects nearly 128 million people in the US and approximately two billion people globally. By understanding real-world needs and partnering with care eye professionals, Tenpoint is working to bring innovation to the aging eye. To learn more, visit tenpointtherapeutics.com and connect on LinkedIn.

For more information about YUVEZZI and full Prescribing Information, please visit www.YUVEZZI.com

Frequently Asked Questions

What is presbyopia?

Summary: Presbyopia is an age related vision condition that gradually reduces the eye’s ability to focus on nearby objects.

Full answer: Presbyopia is a common condition that develops as part of the natural aging process. As the eye’s lens becomes less flexible over time, it becomes more difficult to focus on close up objects such as books, smartphones, menus, and computer screens. The condition affects more than one hundred million adults and is one of the most common age related vision changes worldwide.

Why is there growing interest in presbyopia eye drop treatments?

Summary: Presbyopia eye drops offer a non surgical treatment option designed to improve near vision for adults affected by age related vision changes.

Full answer: Many adults with presbyopia rely on reading glasses or other vision correction methods. Recent advances in ophthalmic treatments have led to the development of prescription eye drops that help improve near vision. These innovations represent a significant advancement in ophthalmic care by providing additional treatment options for patients experiencing presbyopia.

Why is sterile manufacturing important for presbyopia eye drops?

Summary: Sterile manufacturing helps ensure ophthalmic products are produced safely and meet strict quality standards.

Full answer: Eye drops are applied directly to the eye, making sterility a critical requirement throughout the manufacturing process. Manufacturers must follow rigorous quality controls, aseptic production procedures, and validated manufacturing systems to help maintain product safety, consistency, and quality. These standards are especially important for commercial ophthalmic products intended for widespread patient use.

What role does commercial readiness play in launching a new ophthalmic treatment?

Summary: Commercial readiness helps ensure a treatment can be manufactured, supplied, and distributed reliably once it reaches the market.

Full answer: Bringing a new ophthalmic product to market requires more than regulatory approval. Manufacturers must have the production capacity, quality systems, supply chain infrastructure, and operational expertise needed to support product availability. Commercial readiness helps ensure patients have reliable access to treatments after launch.

How does manufacturing experience support ophthalmic product success?

Summary: Manufacturing experience helps support quality, compliance, efficiency, and long term product availability.

Full answer: Producing sterile ophthalmic medications requires specialized expertise and highly controlled manufacturing environments. Manufacturers with extensive experience in ophthalmic production are better equipped to manage complex quality requirements, maintain regulatory compliance, and support consistent product supply throughout the product lifecycle.

What is Blow Fill Seal technology and why is it used for ophthalmic products?

Summary: Blow Fill Seal technology is an advanced aseptic manufacturing process designed to support sterile pharmaceutical production.

Full answer: Blow Fill Seal technology combines container formation, filling, and sealing into a single continuous manufacturing process. This automated approach helps reduce contamination risks while supporting product consistency and sterility assurance. The technology is widely used for ophthalmic and respiratory products that require strict manufacturing controls.

Why is supply chain security important for ophthalmic medications?

Summary: Supply chain security helps ensure patients have consistent access to important treatments.

Full answer: Reliable supply chains are essential for maintaining product availability and minimizing disruptions. In ophthalmic manufacturing, supply chain security involves maintaining production capabilities, quality oversight, inventory management, and operational resilience. Strong supply chain practices help support uninterrupted access to medications for patients and healthcare providers.

How do manufacturing partnerships support pharmaceutical innovation?

Summary: Manufacturing partnerships help transform innovative treatments into commercially available products.

Full answer: The development of new therapies often requires collaboration between pharmaceutical innovators and experienced manufacturers. These partnerships combine scientific innovation with manufacturing expertise, allowing products to move from development and regulatory approval to large scale production and patient access. Successful collaboration helps support both product quality and commercial success.

What qualities are important in an ophthalmic manufacturing partner?

Summary: Quality, sterile manufacturing expertise, reliability, regulatory compliance, and operational experience are key qualities.

Full answer: Selecting a manufacturing partner is a critical decision for ophthalmic products. Important considerations include proven sterile manufacturing capabilities, robust quality systems, supply chain reliability, regulatory compliance, and the ability to support commercial scale production. These factors help ensure products are manufactured safely and consistently.

How can advanced ophthalmic manufacturing benefit patients?

Summary: Advanced manufacturing helps support the delivery of safe, reliable, and high quality ophthalmic treatments.

Full answer: Patients rely on ophthalmic products that are manufactured to the highest standards of quality and safety. Advanced manufacturing technologies, strong quality systems, and experienced production teams help ensure medications are produced consistently and remain available when needed. These capabilities contribute to patient confidence and support positive treatment experiences.